Doliver Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Doliver Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.74M	Hold	374,328	–	–	0.85%	19
2026 Q1	$3.56M	Buy	374,328 +100,000	+36%	+$777K	0.81%	16
2025 Q4	$2.14M	Hold	274,328	–	–	0.54%	28
2025 Q3	$2.08M	Hold	274,328	–	–	0.54%	29
2025 Q2	$2.46M	Buy	274,328 +200,000	+269%	+$1.86M	0.67%	23
2025 Q1	$557K	Hold	74,328	–	–	0.16%	96
2024 Q4	$559K	Sell	74,328 -6,672	-8%	-$50.6K	0.16%	91
2024 Q3	$616K	Hold	81,000	–	–	0.17%	83
2024 Q2	$501K	Hold	81,000	–	–	0.14%	91
2024 Q1	$411K	Hold	81,000	–	–	0.12%	107
2023 Q4	$485K	Hold	81,000	–	–	0.15%	91
2023 Q3	$573K	Hold	81,000	–	–	0.17%	80
2023 Q2	$570K	Hold	81,000	–	–	0.17%	84
2023 Q1	$676K	Hold	81,000	–	–	0.21%	75
2022 Q4	$930K	Hold	81,000	–	–	0.31%	55
2022 Q3	$1.02M	Hold	81,000	–	–	0.38%	45
2022 Q2	$857K	Hold	81,000	–	–	0.3%	60
2022 Q1	$1.32M	Sell	81,000 -19,000	-19%	-$305K	0.42%	43
2021 Q4	$1.52M	Hold	100,000	–	–	0.48%	35
2021 Q3	$1.44M	Buy	+100,000	New	+$1.58M	0.48%	34

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

QFW

QTR Family Wealth Lake Mary, Florida $287M AUM 40.55% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Doliver Advisors's BCRX Position: Q2 2026 in Review

Doliver Advisors held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 374,328 shares worth $3.74M. The position accounts for 0.85% of the portfolio, ranked #19.

Doliver Advisors first reported a position in BCRX in Q3 2021 and has held it in 20 quarters since. 68 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Doliver Advisors held 374,328 shares of BioCryst Pharmaceuticals worth $3.74M as of Q2 2026.
Doliver Advisors left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up 0.85% of Doliver Advisors's portfolio in Q2 2026, its #19 holding.
Doliver Advisors first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
68 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Doliver Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.